Louis Moore Bacon's PTCT Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 44,694 shares of PTC Therapeutics, Inc. (PTCT) worth $3.05 M, representing 0.06% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2018, adding 125,000 shares. Largest reduction occurred in Q1 2020, reducing 170,611 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +44,694 | New Buy | 44,694 | $68.13 |
| Q3 2023 | -25,000 | Sold Out | 0 | $0.00 |
| Q2 2023 | -3,500 | Reduce 12.28% | 25,000 | $40.67 |
| Q1 2023 | -1,500 | Reduce 5.00% | 28,500 | $48.44 |
| Q4 2022 | +10,000 | Add 50.00% | 30,000 | $38.17 |
| Q3 2022 | -20,000 | Reduce 50.00% | 20,000 | $50.20 |
| Q1 2021 | -1,572 | Reduce 3.78% | 40,000 | $47.35 |
| Q4 2020 | -8,428 | Reduce 16.86% | 41,572 | $61.03 |
| Q3 2020 | +10,000 | Add 25.00% | 50,000 | $46.76 |
| Q1 2020 | -170,611 | Reduce 81.01% | 40,000 | $44.60 |
| Q4 2019 | -27,844 | Reduce 11.68% | 210,611 | $48.03 |
| Q3 2019 | +48,337 | Add 25.42% | 238,455 | $33.82 |
| Q2 2019 | +90,118 | Add 90.12% | 190,118 | $45.00 |
| Q1 2019 | +10,000 | Add 11.11% | 100,000 | $37.64 |
| Q4 2018 | -10,000 | Reduce 10.00% | 90,000 | $34.32 |
| Q2 2018 | -75,000 | Reduce 42.86% | 100,000 | $33.73 |
| Q1 2018 | +125,000 | Add 250.00% | 175,000 | $27.06 |
| Q3 2017 | -50,000 | Reduce 50.00% | 50,000 | $20.02 |
| Q1 2017 | +50,000 | Add 100.00% | 100,000 | $9.84 |
| Q4 2016 | -50,000 | Reduce 50.00% | 50,000 | $10.92 |
| Q3 2016 | +100,000 | New Buy | 100,000 | $14.01 |
| Q3 2015 | -43,000 | Sold Out | 0 | $0.00 |
| Q2 2015 | +23,000 | Add 115.00% | 43,000 | $48.14 |
| Q1 2015 | +20,000 | New Buy | 20,000 | $60.85 |
Louis Moore Bacon's PTC Therapeutics Investment FAQs
Louis Moore Bacon first purchased PTC Therapeutics, Inc. (PTCT) in Q1 2015, acquiring 20,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held PTC Therapeutics, Inc. (PTCT) for 33 quarters since Q1 2015.
Louis Moore Bacon's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2018, adding 175,000 shares worth $4.74 M.
According to the latest 13F filing for Q1 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 44,694 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $3.05 M.
As of the Q1 2026 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.06% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in PTC Therapeutics, Inc. (PTCT) was 238,455 shares, as reported at the end of Q3 2019.